Raleigh, NC (PRWEB) April 09, 2014
A team of Egyptian biochemists say angiogenin and clusterin – two proteins vital to certain cellular processes – could make bladder cancer diagnosis more accurate and treatments more effective. Click here to read details on the study which has just been posted on the Cancer Monthly website.
Researchers with the Faculty of Pharmaceutical Sciences and Pharmaceutical Technologies at Future University in Cairo evaluated the merits of testing for angiogenin and clusterin in the urine, along with standard urine cytology. Currently, cytology (looking for cancer cells in urine) and cystoscopy (examination of the bladder with a camera) are the primary tools used to detect suspected bladder cancer.
“Combined use of the cytology with the studied biomarkers can improve the sensitivity for detecting bladder cancer, and may be very useful in monitoring the effectiveness of antiangiogenic and apoptotic therapies in bladder cancer,” says researcher Marwa Shabayek, lead author of the study.
The study published in Pathology and Oncology Research involved 50 patients with malignant bladder cancer, 20 with benign bladder tumors, and 20 healthy subjects.
“It stands to reason that a test that improves the diagnosis of bladder cancer has the potential to also improve survival,” says Cancer Monthly’s Managing Editor Alex Strauss. “This is especially encouraging news for diabetics, who live with a higher risk for bladder cancer anyway.” Research suggests that the risk for bladder cancer in diabetics is compounded by the drug Actos.
To learn more about the new biomarker study, including just how accurate the test may be, see New Biomarkers May Advance Bladder Cancer Diagnosis and Treatment, now available on the Cancer Monthly website.
Shabayek, MI et al, “Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarkers for bladder cancer”, April 3, 2014, Pathology and Oncology Research, Epub ahead of print, http://www.ncbi.nlm.nih.gov/pubmed/24696417.
For over ten years, Cancer Monthly has been the only centralized source of cancer treatment results. Patients can see the actual survival rate, quality-of-life indicators, and other key data for approximately 1,500 different cancer treatments. Cancer Monthly provides timely and ground-breaking news on the causes, diagnoses and treatments of the most common cancers including Bladder, Brain, Breast, Colon, Kidney (Renal), Liver, Lung (NSCLC), Ovarian, Prostate and Rectal Cancers, Melanoma, Mesothelioma, and Non-Hodgkin's Lymphoma. Written for patients and their loved ones, Cancer Monthly helps families make more informed treatment decisions.